Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. / Mukama, Trasias; Fortner, Renée Turzanski; Katzke, Verena; Hynes, Lucas Cory; Petrera, Agnese; Hauck, Stefanie M; Johnson, Theron; Schulze, Matthias; Schiborn, Catarina; Rostgaard-Hansen, Agnetha Linn; Tjønneland, Anne; Overvad, Kim; Pérez, María José Sánchez; Crous-Bou, Marta; Chirlaque, María-Dolores; Amiano, Pilar; Ardanaz, Eva; Watts, Eleanor L; Travis, Ruth C; Sacerdote, Carlotta; Grioni, Sara; Masala, Giovanna; Signoriello, Simona; Tumino, Rosario; Gram, Inger T; Sandanger, Torkjel M; Sartor, Hanna; Lundin, Eva; Idahl, Annika; Heath, Alicia K; Dossus, Laure; Weiderpass, Elisabete; Kaaks, Rudolf.
In: British Journal of Cancer, Vol. 126, No. 9, 2022, p. 1301-1309.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer
AU - Mukama, Trasias
AU - Fortner, Renée Turzanski
AU - Katzke, Verena
AU - Hynes, Lucas Cory
AU - Petrera, Agnese
AU - Hauck, Stefanie M
AU - Johnson, Theron
AU - Schulze, Matthias
AU - Schiborn, Catarina
AU - Rostgaard-Hansen, Agnetha Linn
AU - Tjønneland, Anne
AU - Overvad, Kim
AU - Pérez, María José Sánchez
AU - Crous-Bou, Marta
AU - Chirlaque, María-Dolores
AU - Amiano, Pilar
AU - Ardanaz, Eva
AU - Watts, Eleanor L
AU - Travis, Ruth C
AU - Sacerdote, Carlotta
AU - Grioni, Sara
AU - Masala, Giovanna
AU - Signoriello, Simona
AU - Tumino, Rosario
AU - Gram, Inger T
AU - Sandanger, Torkjel M
AU - Sartor, Hanna
AU - Lundin, Eva
AU - Idahl, Annika
AU - Heath, Alicia K
AU - Dossus, Laure
AU - Weiderpass, Elisabete
AU - Kaaks, Rudolf
N1 - Publisher Copyright: © 2022, The Author(s).
PY - 2022
Y1 - 2022
N2 - Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. Methods: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. Results: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. Conclusion: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
AB - Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. Methods: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. Results: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. Conclusion: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
U2 - 10.1038/s41416-021-01697-z
DO - 10.1038/s41416-021-01697-z
M3 - Journal article
C2 - 35031764
AN - SCOPUS:85122722777
VL - 126
SP - 1301
EP - 1309
JO - The British journal of cancer. Supplement
JF - The British journal of cancer. Supplement
SN - 0007-0920
IS - 9
ER -
ID: 305697084